New combo aims to control prostate cancer without sacrificing erections

NCT ID NCT04025372

Ongoing Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a newer hormone therapy (darolutamide) plus radiation against standard hormone therapy plus radiation for men with intermediate-risk prostate cancer. The goal is to see if the new approach controls the cancer just as well while helping men keep better erectile function. About 234 men are taking part in this phase 2 trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERMEDIATE RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Associated Medical Professionals of NY

Syracuse, New York, 13210, United States
Beth Israel Deaconness Medical Center

Boston, Massachusetts, 02115, United States
Brigham and Women Hospital

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center

Milford, Massachusetts, 01757, United States
Dana-Farber/Brigham and Women's Cancer Center in Clinical Affiliation with South Shore Hospital

South Weymouth, Massachusetts, 02190, United States
NYU Langone Health

New York, New York, 10016, United States
NYU Long Island

Garden City, New York, 11530, United States
Stamford Hospital

Stamford, Connecticut, 06904, United States
Washington University School of Medicine in St. Louis

St Louis, Missouri, 63108, United States
XCancer Omaha / Urology Cancer Center

Omaha, Nebraska, 68130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.